EU External Trade - Products and preparations for pharmaceutical or surgical uses, Intermediate products of the antibiotics manufacturing process obtained from the fermentation of Streptomyces tenebrarius, whether or not dried, for use in the manufacture of human medicaments of heading|3004

Extra-EU sourcing of Products and preparations for pharmaceutical or surgical uses, Intermediate products of the antibiotics manufacturing process obtained from the fermentation of Streptomyces tenebrarius, whether or not dried, for use in the manufacture of human medicaments of heading|3004 is highly concentrated. 🇬🇧 United Kingdom captures 84.5% of imports (€535K), followed by 🇨🇭 Switzerland (8.3%). With an HHI of 7243, this Concentrated market exposes the EU to supply dependency risks.

The main extra-EU export markets for Products and preparations for pharmaceutical or surgical uses, Intermediate products of the antibiotics manufacturing process obtained from the fermentation of Streptomyces tenebrarius, whether or not dried, for use in the manufacture of human medicaments of heading|3004 are 🇦🇺 Australia, 🇨🇭 Switzerland, 🇺🇸 United States. 🇦🇺 Australia absorbs 30.6% of European exports (€623K).

Within the EU, 🇳🇱 Netherlands concentrates 81.6% of Products and preparations for pharmaceutical or surgical uses, Intermediate products of the antibiotics manufacturing process obtained from the fermentation of Streptomyces tenebrarius, whether or not dried, for use in the manufacture of human medicaments of heading|3004 imports, well ahead of 🇬🇷 Greece (8.3%). The top importing member states are 🇳🇱 Netherlands, 🇬🇷 Greece, 🇲🇹 Malta.

The year 2025 marked a turning point: both imports and exports were falling sharply, shifting by -85.5% and -63.9% respectively.